01
Physical Boten project
Facility development, planned production modules, implementation sequencing and the evidence needed before routine operation.
Boten contextCompany
A pharmaceutical manufacturing project being developed in Boten.
Luang Pharma is the brand used for a development-stage pharmaceutical manufacturing programme in Lao PDR. The controlled website record separates the physical Boten project, the broader generic product portfolio and future market-access work.
- Public identity
- Luang PharmaProject brand
- Project base
- Boten Economic Zone, Lao PDR
- Source basis
- 15 June 2026 project brief + company-supplied project record
- Current stage
- Construction and fit-outIn progress · reviewed 13 September 2026
01 · Company position
Company story without overstating the operating stage.
The immediate programme is the establishment of a manufacturing facility and the foundations needed for future pharmaceutical operations.
Programme purpose
The controlled project material describes the development of a pharmaceutical manufacturing facility in Boten. The immediate website purpose is to explain that programme accurately: what the initial engineering plan contains, how the public portfolio relates to it, what evidence would be required for operation, and how professional enquiries are scoped.
Identity and documents
The registered operator and its registration particulars are identified in the company information notice. The shared public identity is Luang Pharma.
The company profile (PDF) summarises the company, its stage and roadmap, the planned modules, the portfolio and the contact route in one document, generated from the same records as this website.
Stage boundary
A construction project, installed equipment, qualified systems, a manufacturing authorisation, a registered medicine and an available commercial supply are different milestones. This website does not collapse them into one claim.
02 · Programme architecture
Three connected workstreams with different evidence tests.
02
Generic product portfolio
Public development records organised by generic identity and presentation. Portfolio inclusion does not establish a manufacturing route, approval or availability.
Product portfolio
03
Market and partner assessment
Product- and destination-specific discussion of regulatory roles, supply-chain responsibilities and the information needed before a commercial pathway can be defined.
Partnering processIt does not depict Luang Pharma's project, products or installed equipment.
03 · Initial manufacturing plan
The June 2026 project brief describes two planned modules.
The wider portfolio contains other dosage forms, devices and diagnostics. Their presence is a development roadmap, not proof that corresponding Boten production lines exist. Review the scope distinction.
Module 01Planned
Formulation & filling
The source plan identifies five presentation families: lyophilised vials, dual-chamber cartridges, single-chamber lyophilised cartridges, 10 mL oil-based vial injections and 1 mL ampoules.
Module 02Planned
Protein raw-material production & purification
A separate planned module is described for protein raw-material production and purification. The source does not by itself establish a validated process, specific product, installed state or authorised production scope.
Broader services
The planned capabilities catalogue is a proposed expansion of scope, with technical inclusion still to be confirmed. Explore the catalogue
04 · Place & purpose
A Lao base for future development.
Boten Economic Zone is the location identified in the project record. Geographic context can help explain the project; it does not establish distribution rights, an export network or authorisation in another market.
Read the company through its separate evidence layers
05 · Project record
Documents and photographs answer different questions.
Project evidence is described by status and date; planning material is not treated as operating proof.
The supplied meeting and site-visit photographs can show project activity and context. They do not demonstrate inspection, regulatory approval or a commercial partnership. Earlier construction footage records a physical construction stage but does not establish the site’s current completion state.
- Planning source
- Boten Biopharmaceutical Manufacturing Project · 15 June 2026Describes the initial project architecture and implementation sequence.
- Current project stage
- Construction and fit-out · in progressProject status reviewed 13 September 2026.
- Next milestone
- Equipment installation and qualificationTarget Q1 2027 · indicative.
- Photographic record
- Deduplicated owner-authorised project images with neutral captions
- Exterior derivatives
- Not used in current public pages while editing provenance remains unresolved
06 · Evidence boundaries
What the current controlled record can support.
- Supported for website use
- Brand, Boten project context, dated initial planning scope, owner-authorised project photography.
- Still requires controlled evidence
- Current licence/certificate matrix, present installed-line status, current staffing, named partnerships and current market authorisations.
- Held from public copy
- Exact facility area, private financial forecasts and unsupported third-party endorsement claims.
| Subject | What it establishes | What remains separate |
|---|---|---|
| Project brief | Documented development intent | Installed state and operating readiness |
| Construction activity | Physical project development | Qualification and authorisation |
| Portfolio inclusion | A public development record | Registration and supply |
| Quality framework | Requirements and workstreams | Approved and implemented systems |
Professional enquiries
Discuss a defined Luang Pharma project question.
State your organisation, the subject you need to assess and the relevant country or technical context.